SPRY Earnings

SPRY reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of 29.48M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.42 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SPRY's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, SPRY's stock price tends to shift by an average of 1.38% in the 10 days leading up to earnings and 11.22% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SPRY's annual revenue to reach 26.90M, while the EPS is projected at -0.43. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SPRY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SPRY's stock price typically moves by 1.38% in the 10 days before its earnings and 11.22% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.43 and revenue of 26.90M.

The company reported strong growth in neffy prescriptions and revenue, with a 2.5-fold increase in U.S. net product revenue. Despite a net loss, the financial health remains stable with significant cash reserves. The Q&A highlighted positive feedback from new initiatives and optimism about future growth through partnerships and expanded market access. While some uncertainties exist, such as reliance on a term loan and inconsistent institutional sales, the overall sentiment is positive due to revenue growth, strategic initiatives, and optimistic guidance.